152 related articles for article (PubMed ID: 10413425)
1. Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo.
Aghi M; Kramm CM; Breakefield XO
J Natl Cancer Inst; 1999 Jul; 91(14):1233-41. PubMed ID: 10413425
[TBL] [Abstract][Full Text] [Related]
2. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
[TBL] [Abstract][Full Text] [Related]
3. Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate.
Sohn KJ; Smirnakis F; Moskovitz DN; Novakovic P; Yates Z; Lucock M; Croxford R; Kim YI
Gut; 2004 Dec; 53(12):1825-31. PubMed ID: 15542523
[TBL] [Abstract][Full Text] [Related]
4. Targeted expression of human folylpolyglutamate synthase for selective enhancement of methotrexate chemotherapy in osteosarcoma cells.
Bienemann K; Staege MS; Howe SJ; Sena-Esteves M; Hanenberg H; Kramm CM
Cancer Gene Ther; 2013 Sep; 20(9):514-20. PubMed ID: 23949282
[TBL] [Abstract][Full Text] [Related]
5. Folylpoly-γ-glutamate synthetase: A key determinant of folate homeostasis and antifolate resistance in cancer.
Raz S; Stark M; Assaraf YG
Drug Resist Updat; 2016 Sep; 28():43-64. PubMed ID: 27620954
[TBL] [Abstract][Full Text] [Related]
6. Re: Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo.
Jansen G; Peters GJ; Pinedo HM; Priest DG; Assaraf YG
J Natl Cancer Inst; 1999 Dec; 91(23):2047-50. PubMed ID: 10580033
[No Abstract] [Full Text] [Related]
7. Folylpoly-gamma-glutamate synthetase: generation of isozymes and the role in one carbon metabolism and antifolate cytotoxicity.
Qi H; Atkinson I; Xiao S; Choi YJ; Tobimatsu T; Shane B
Adv Enzyme Regul; 1999; 39():263-73. PubMed ID: 10470377
[TBL] [Abstract][Full Text] [Related]
8. Cross-resistance studies of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines.
McGuire JJ; Heitzman KJ; Haile WH; Russell CA; McCloskey DE; Piper JR
Leukemia; 1993 Dec; 7(12):1996-2003. PubMed ID: 8255099
[TBL] [Abstract][Full Text] [Related]
9. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia.
Stark M; Wichman C; Avivi I; Assaraf YG
Blood; 2009 Apr; 113(18):4362-9. PubMed ID: 19131550
[TBL] [Abstract][Full Text] [Related]
10. Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells.
Cho RC; Cole PD; Sohn KJ; Gaisano G; Croxford R; Kamen BA; Kim YI
Mol Cancer Ther; 2007 Nov; 6(11):2909-20. PubMed ID: 18025275
[TBL] [Abstract][Full Text] [Related]
11. Differing specificities for 4-aminofolate analogues of folylpolyglutamyl synthetase from tumors and proliferative intestinal epithelium of the mouse with significance for selective antitumor action.
Rumberger BG; Barrueco JR; Sirotnak FM
Cancer Res; 1990 Aug; 50(15):4639-43. PubMed ID: 2369741
[TBL] [Abstract][Full Text] [Related]
12. Folylpolyglutamate synthetase expression in antifolate-sensitive and -resistant human cell lines.
McGuire JJ; Russell CA
Oncol Res; 1998; 10(4):193-200. PubMed ID: 9778690
[TBL] [Abstract][Full Text] [Related]
13. Variable expression of the folylpolyglutamate synthetase gene at the level of mRNA transcription in human leukemia cell lines sensitive, or made resistant, to various antifolate drugs.
Takemura Y; Kobayashi H; Miyachi H
Anticancer Drugs; 1999 Aug; 10(7):677-83. PubMed ID: 10507318
[TBL] [Abstract][Full Text] [Related]
14. Enhancing cytotoxic sensitivity of tumor cells to antifolates: another opportunity for gene therapy?
Sirotnak FM
J Natl Cancer Inst; 1999 Jul; 91(14):1178-9. PubMed ID: 10413407
[No Abstract] [Full Text] [Related]
15. Molecular analysis of murine leukemia cell lines resistant to 5, 10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase.
Zhao R; Titus S; Gao F; Moran RG; Goldman ID
J Biol Chem; 2000 Aug; 275(34):26599-606. PubMed ID: 10856298
[TBL] [Abstract][Full Text] [Related]
16. Different antifolate-resistant L1210 cell variants with either increased or decreased folylpolyglutamate synthetase gene expression at the level of mRNA transcription.
Roy K; Mitsugi K; Sirlin S; Shane B; Sirotnak FM
J Biol Chem; 1995 Nov; 270(45):26918-22. PubMed ID: 7592937
[TBL] [Abstract][Full Text] [Related]
17. Preferential selection during therapy in vivo by edatrexate compared to methotrexate of resistant L1210 cell variants with decreased folylpolyglutamate synthetase activity.
Rumberger BG; Schmid FA; Otter GM; Sirotnak FM
Cancer Commun; 1990; 2(9):305-10. PubMed ID: 2206778
[TBL] [Abstract][Full Text] [Related]
18. [The mbr-FPGS efficient expression plasmid enhances the sensitivity of Jurkat cells to methotrexate].
Hu WJ; Sun YJ
Yi Chuan; 2012 Jun; 34(6):705-10. PubMed ID: 22698741
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of folylpolyglutamate synthetase gene expression in tumor tissues by the polymerase chain reaction: marked variation of expression among leukemia patients.
Lenz HJ; Danenberg K; Schnieders B; Goeker E; Peters GJ; Garrow T; Shane B; Bertino JR; Danenberg PV
Oncol Res; 1994; 6(7):329-35. PubMed ID: 7865908
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biologic activity of new side-chain-altered methotrexate and aminopterin analogs with dual inhibitory action against dihydrofolate reductase and folylpolyglutamate synthetase.
Rosowsky A; Moran RG; Freisheim JH; Bader H; Forsch RA; Solan VC
NCI Monogr; 1987; (5):145-52. PubMed ID: 3431589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
